Pharmaceutical Business Ratings Overview

For our Q210 Pharmaceutical Business Environment Ratings for the Middle East and Africa (MEA), BMI has placed the UAE in pole position, while Zimbabwe will remain in its characteristic last place of the 17 countries that we cover in the region. While Zimbabwe's continued presence at the bottom of the table underlines the country's ongoing economic difficulties and therefore makes it a highly risky market for foreign direct investment (FDI), the UAE has emerged as the region's consistent leading player. Saudi Arabia has moved into second place, knocking South Africa down to sixth.

To read the full article, please choose one of the following options: